.Creating value through therapeutic innovation
About NicOx Products Maximizing portfolio People Investor & media
Profile
Pipeline		 Naproxcinod
NCX 6560
 Full portfolio		 Co-development
Alliances
Technology		 Board of Directors
Management Team
Contacts
Careers		 Press releases
 Investor relations
Fact file
Financials
Corporate governance
"Informations Réglementées"


 

2008 Company Report

2008 Financial Report
  News......
 2010 Financial calendar 
22 January, 2010 NicOx announces EMEA validation of naproxcinod MAA submission 
 NicOx to present at the 28th Annual J.P. Morgan  Healthcare Conference  on January 14th 
 
12 January, 2010 NicOx and Topigen Pharmaceuticals terminate collaboration following the acquisition of TOPIGEN by Pharmaxis
22 December, 2009 NicOx submits naproxcinod MAA to the EMEA
18 November, 2009 NicOx announces FDA accepts naproxcinod NDA for filing 

NicOx is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs for unmet medical needs.
NicOx is targeting the therapeutic areas of inflammatory and cardiometabolic diseases.
NicOx aims to build itself into a self-sustaining, fully integrated bio-pharmaceutical company.

Nitric Oxide
Knowledge Center
NO-knowledge center
Conferences Directions to NicOx Legal notice Site en français